Phase II and long-term follow-up treatment of MS patients with MBP8298, recently published in the European Journal of Neurology showed that MBP8298 safely delayed the median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.
MBP8298 is being developed in three late-stage clinical trials:
- MAESTRO-01: A pivotal phase III trial in Canada and Western Europe
evaluating MBP8298 for the treatment of secondary progressive
multiple sclerosis (SPMS). The trial is a randomized, double-blind
study and is fully recruited with 611 patients.
- MAESTRO-03: A pivotal phase III U.S. trial evaluating MBP8298 for the
treatment of SPMS. The trial is a randomized, double-blind study
enrolling approximately 510 patients.
- MINDSET-01: A phase II trial evaluating MBP8298 for the treatment of
relapsing remitting multiple sclerosis (RRMS). The trial is a
randomized, double-blind study and is fully recruited with 218
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which
reflect the Com
|SOURCE BioMS Medical Corp.|
Copyright©2007 PR Newswire.
All rights reserved